April 2012 in “The Journal of Urology” Persistent ED in Propecia users is not due to abnormal blood flow.
75 citations
,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
5 citations
,
January 2010 in “Acta Chirurgica Iugoslavica” Higher urethral PSA levels after prostate removal may be linked to more scalp hair loss and more PSA in urethral glands.
14 citations
,
November 2006 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
2 citations
,
March 2020 in “Baghdad Science Journal” Finasteride effectively reduces DHT and E2 levels, helping with prostate enlargement.
June 2024 in “Research Square (Research Square)” Finasteride overdose can cause acute pancreatitis.
PRP injections with tadalafil and stretching safely improved Peyronie's symptoms but didn't significantly change curvature long-term.
49 citations
,
September 1986 in “British Journal of Dermatology” Hidradenitis suppurativa improves with antiandrogen therapy.
Men with benign prostate hyperplasia have more meibomian gland loss and tear film problems.
2 citations
,
January 2004 in “Korean Journal of Andrology” Finasteride impairs sperm quality and fertility in rats, even after stopping treatment.
November 2005 in “The Journal of Urology” Dutasteride may lower the chance of finding prostate cancer in men with enlarged prostates.
41 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
January 2010 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” Finasteride may be a promising treatment for recurrent priapism in sickle cell anemia.
March 2026 in “Food Science & Nutrition” Arachis hypogaea L. root extract reduces prostate enlargement and inflammation in mice.
3 citations
,
June 1999 in “The Prostate” Finasteride reduces PSA levels, terazosin doesn't affect them, and tracking prostate cancer in patients taking finasteride could be difficult.
April 2011 in “Journal of physiology and pharmacology : an official journal of the Polish Physiological Society” Men with urinary issues often don't stick to their medication long-term.
3 citations
,
March 2020 in “The Journal of Urology” Older patients sticking to their prostate medication saw lasting health benefits.
44 citations
,
October 2010 in “BJUI” 5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.
November 2025 in “BMC Urology” Larger prostate size, longer surgery, and smoking increase risks, while finasteride and experienced surgeons reduce them during prostate surgery.
5 citations
,
January 2018 in “Research Journal of Pharmacy and Technology” Finasteride significantly reduces fertility in male rats.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
October 2024 in “Journal of the Endocrine Society” Post-finasteride syndrome can cause lasting sexual, physical, and mental health issues with limited treatment options.
April 2005 in “The Journal of Urology”
January 2018 in “Repositorio de Tesis - UNMSM” Physalis peruviana extract is more effective in treating benign prostatic hyperplasia in rats than finasteride and terazosine.
April 2016 in “The Journal of Sexual Medicine” PFS affects some women, steroids easily bought online, hypogonadism info unreliable, low testosterone linked to CVD.
1 citations
,
October 2006 in “Oncology times” Finasteride improves prostate cancer detection in PSA test.
1 citations
,
January 2013 in “Shandong yiyao” Preoperative finasteride can help prevent and reduce transurethral resection syndrome.
99 citations
,
April 2005 in “Journal of Dermatological Treatment” Finasteride effectively treats hidradenitis suppurativa for most patients.
97 citations
,
December 2011 in “New England Journal of Medicine” The FDA did not approve certain drugs for prostate cancer prevention due to concerns about their effectiveness and potential risks.